Search Results
MC# 22-04
A Phase I Study of BAL0891 as Monotherapy and in Combination with Chemotherapy in Patients with Advanced Solid Tumors
MC# 22-08
A First-in-Human, Multicenter, Phase I/II, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors
MC# 22-12
A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants with Advanced Solid Tumors
MC# 22-13
A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors
MC# 22-14
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors
MC# 22-20
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors
MC# 22-29
A Phase I, Open-Label, Dose Escalation and Expansion Study of PF-07265028 as a Single Agent and in Combination with Sasanlimab Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PF-07265028 in Participants with Advanced or Metastatic Solid Tumors
MC# 23-03
A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors
MC# 18-26
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
MC# 20-15
A Phase I First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors
MC# 21-07
An Open-Label, Multi-Center Phase I/Ib Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors
MC# 21-17
A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
MC# 21-36
An Open-Label, Multicenter, Phase I Study Of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed and/or Refractory Solid Cancers
MC# 21-39
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab and Epacadostat
MC# 19-25
A Phase Ib Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects with Previously Treated Advanced HER2-positive Solid Tumors
MC# 22-09
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
MC# 22-31
A Phase I Trial of SIM1811-03 in Subjects with Advanced Solid Tumors and Cutaneous T-cell Lymphoma
MC# 22-35
A Phase I/II, Open-Label, Multicenter Study of Oral MRT-2359 in Patients with MYC-driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-Cell Lymphoma
MC# 22-37
A Phase I/IIa, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors
MC# 23-01
A Phase I Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors
MC# 23-05
A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients with High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
MC# 22-36
An Open-Label Phase Ib Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
MC# 19-37
Subprotocol L: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with BI 1701963 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation
MC# 20-08
An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
MC# 21-10
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
